Butcher's Broom for Health & Longevity - Quick Reference Sheet

Butcher's Broom for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 3.1 – Audit

Butcher's Broom is a Mediterranean shrub whose root extract is used to maintain leg vein tone and ease leg swelling, heaviness, and cramping. Medium-level, largely industry-funded evidence shows oral extracts reduce leg swelling and vein discomfort, mostly in formulas with citrus compounds and vitamin C. Single-herb oral use matches placebo tolerability, while combination formulas carry a rare risk of reversible colon inflammation and watery diarrhea. (Full Review)

Protocol

Standardized single-herb protocol (German Commission E approach)
72–75 mg daily dry extract
Delivering 7–11 mg total ruscogenins, studied as 36 mg twice daily
European combination protocol
300–450 mg daily Ruscus extract
2–3 Cyclo 3 Fort capsules daily (150 mg Ruscus extract, 150 mg hesperidin methyl chalcone [HMC, citrus flavonoid], and 100 mg vitamin C per capsule)
Single morning dose versus split dosing
Once each morning or twice daily
Two Cyclo 3 Fort capsules once each morning matched twice-daily split dosing in efficacy and tolerability
Time to effect
Chronic Venous Insufficiency and Lower-Limb Edema Relief
2 to 12 weeks
Microscopic capillary imaging and limb blood-volume improvements begin within 2 weeks; maximal leg volume and ankle circumference reductions accrue over 8 to 12 weeks
Secondary Lymphedema Volume Reduction
3 months
Arm edema volume decreased by 12.9% more than placebo over 3 months with combination therapy
Hemorrhoidal Symptom Relief
2 to 6 weeks
Acute hemorrhoid courses run 2 to 6 weeks, with symptom score and bleeding reductions observed at 30 days

Benefits

Contraindications
  • Children and adolescents (<18 years)
  • Pregnant and lactating women
  • Individuals with uncontrolled diabetes or prior diabetic ketoacidosis
  • Individuals with lymphocytic or microscopic colitis or chronic unexplained diarrhea
  • Individuals with ruscogenin allergy or decompensated cardiac or renal edema
Key Interactions
  • Alpha-adrenergic antagonists (prazosin, doxazosin, tamsulosin, terazosin)
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline) and alpha-agonists (midodrine)
  • Antidiabetic medications (insulin, metformin, glimepiride, empagliflozin)
  • Over-the-counter sympathomimetic decongestants (pseudoephedrine, phenylephrine, oxymetazoline)
  • Adrenergic and stimulant supplements (bitter orange, ephedra, yohimbine)
  • Venoactive and capillary-stabilizing supplements (horse chestnut seed extract, micronized diosmin, hesperidin, gotu kola)
  • Compression stockings and manual lymphatic drainage

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal Distress and Lymphocytic Colitis; Allergic Contact Dermatitis; Diabetic Ketoacidosis and Metabolic Acidosis; Cytolytic Hepatitis
  • Speculative: Saponin-Induced Erythrocyte Hemolysis; Vasoconstriction-Mediated Arterial Blood Pressure Elevation

Monitoring

Marker Target Why
Ankle and Calf Circumference / Lower-Limb Volume No established target; reduction from baseline (e.g., −16.5 to −20.5 mL leg volume or −0.58 cm ankle circumference) Efficacy marker: expected to decrease as venous tone and capillary sealing improve.
Seated and Standing Blood Pressure No established target; seated and standing blood pressure change from individual baseline Safety check and efficacy marker: detects unwanted arterial pressor shifts or improved orthostatic stability.
Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) 10–40 U/L (ALT); 10–35 U/L (AST) (standard reference range) Safety check: detects rare drug-induced cytolytic hepatitis (liver cell injury); enzyme elevation above reference range prompts cessation.
Fasting Plasma Glucose, Serum Potassium, and Bicarbonate 70–99 mg/dL (glucose); 3.5–5.0 mmol/L (potassium); 22–29 mmol/L (bicarbonate) (standard reference range) Safety check: detects elevated blood glucose, ketoacidosis (ketone acid buildup), high potassium, or diarrhea-induced low potassium prompting cessation.

Cadence: Baseline evaluation before starting; blood pressure and fasting glucose at 1–2 weeks; limb circumference and venous symptoms at 4, 8, and 12 weeks; liver transaminases and serum electrolytes at 4–8 weeks (then every 3–6 months during seasonal cycles), or immediately if persistent watery diarrhea or systemic symptoms develop.

Qualitative Assessment

  • Evening leg heaviness and tension: Weekly assessment for progressive relief over 2–12 weeks.
  • Nocturnal calf cramping and tingling: Frequency of nighttime awakenings.
  • Bowel habit consistency: Emergence of new watery stools prompting immediate cessation.